165 related articles for article (PubMed ID: 17997105)
1. Non-classical actions of testosterone: an update.
Rahman F; Christian HC
Trends Endocrinol Metab; 2007 Dec; 18(10):371-8. PubMed ID: 17997105
[TBL] [Abstract][Full Text] [Related]
2. Membrane-initiated steroid action in breast and prostate cancer.
Kampa M; Pelekanou V; Castanas E
Steroids; 2008 Oct; 73(9-10):953-60. PubMed ID: 18249430
[TBL] [Abstract][Full Text] [Related]
3. Rapid actions of androgens.
Michels G; Hoppe UC
Front Neuroendocrinol; 2008 May; 29(2):182-98. PubMed ID: 17983646
[TBL] [Abstract][Full Text] [Related]
4. Rapid membrane effect of testosterone in LNCaP cells.
Wang Z; Liu L; Hou J; Wen D; Yan C; Pu J; Ouyang J; Pan H
Urol Int; 2008; 81(3):353-9. PubMed ID: 18931557
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer: a model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model.
Bonaccorsi L; Nosi D; Quercioli F; Formigli L; Zecchi S; Maggi M; Forti G; Baldi E
Steroids; 2008 Oct; 73(9-10):1030-7. PubMed ID: 18358509
[TBL] [Abstract][Full Text] [Related]
6. Rapid estrogen actions in the cardiovascular system.
Simoncini T; Mannella P; Genazzani AR
Ann N Y Acad Sci; 2006 Nov; 1089():424-30. PubMed ID: 17261785
[TBL] [Abstract][Full Text] [Related]
7. Membrane androgen receptor activation in prostate and breast tumor cells: molecular signaling and clinical impact.
Papadopoulou N; Papakonstanti EA; Kallergi G; Alevizopoulos K; Stournaras C
IUBMB Life; 2009 Jan; 61(1):56-61. PubMed ID: 19109827
[TBL] [Abstract][Full Text] [Related]
8. Candidates for membrane progestin receptors--past approaches and future challenges.
Zhu Y; Hanna RN; Schaaf MJ; Spaink HP; Thomas P
Comp Biochem Physiol C Toxicol Pharmacol; 2008 Nov; 148(4):381-9. PubMed ID: 18602498
[TBL] [Abstract][Full Text] [Related]
9. [Non-genomic actions of steroids: mechanism and significance].
Wang YX; Liu L; Long F; Feng-Yong Y; Jiang CL
Sheng Li Ke Xue Jin Zhan; 2005 Oct; 36(4):304-8. PubMed ID: 16408767
[TBL] [Abstract][Full Text] [Related]
10. Androgen actions and the ovary.
Walters KA; Allan CM; Handelsman DJ
Biol Reprod; 2008 Mar; 78(3):380-9. PubMed ID: 18003945
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-reductase isozymes and androgen actions in the prostate.
Zhu YS; Imperato-McGinley JL
Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
[TBL] [Abstract][Full Text] [Related]
12. Non-genomic actions of estrogens and their interaction with genomic actions in the brain.
Vasudevan N; Pfaff DW
Front Neuroendocrinol; 2008 May; 29(2):238-57. PubMed ID: 18083219
[TBL] [Abstract][Full Text] [Related]
13. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.
Ho LL; Kench JG; Handelsman DJ; Scheffer GL; Stricker PD; Grygiel JG; Sutherland RL; Henshall SM; Allen JD; Horvath LG
Prostate; 2008 Sep; 68(13):1421-9. PubMed ID: 18615486
[TBL] [Abstract][Full Text] [Related]
14. Non-genomic progesterone actions in female reproduction.
Gellersen B; Fernandes MS; Brosens JJ
Hum Reprod Update; 2009; 15(1):119-38. PubMed ID: 18936037
[TBL] [Abstract][Full Text] [Related]
15. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity.
Rettew JA; Huet-Hudson YM; Marriott I
Biol Reprod; 2008 Mar; 78(3):432-7. PubMed ID: 18003947
[TBL] [Abstract][Full Text] [Related]
16. Nongenomic actions of aldosterone: physiological or pathophysiological role?
Mihailidou AS
Steroids; 2006 Apr; 71(4):277-80. PubMed ID: 16280143
[TBL] [Abstract][Full Text] [Related]
17. Diverse FSH and testosterone signaling pathways in the Sertoli cell.
Loss ES; Jacobus AP; Wassermann GF
Horm Metab Res; 2007 Nov; 39(11):806-12. PubMed ID: 17992635
[TBL] [Abstract][Full Text] [Related]
18. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
19. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
20. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Morgentaler A
J Urol; 2009 Mar; 181(3):972-9. PubMed ID: 19150547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
